PYCR1 and Insulin resistance: This work further emphasizes the importance of the plasma metabolite PA and its interaction with innate insulin resistance within the context of the PYCR1 inhibition-mediated Akt/mTOR signalling involved in the manifestation of LDR + HFD-associated metabolic impairment (Fig. 9).